BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A. Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 2011;11:4. [PMID: 21241463 DOI: 10.1186/1471-230x-11-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorldJournal 2013;2013:931972. [PMID: 23431262 DOI: 10.1155/2013/931972] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
2 Yamasaki A, Umeno N, Harada S, Tanaka K, Kato M, Kotoh K. Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib. J Gastrointest Oncol 2016;7:E36-40. [PMID: 27284486 DOI: 10.21037/jgo.2015.10.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Atkin C, Earwaker P, Pallan A, Shetty S, Punia P, Ma YT. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. BMC Gastroenterol 2017;17:30. [PMID: 28193171 DOI: 10.1186/s12876-017-0585-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Tan-Shalaby JL. Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel. BMJ Case Rep 2014;2014:bcr2014203962. [PMID: 25178887 DOI: 10.1136/bcr-2014-203962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Anwar F, Singh R, Mushtaq G, Al-maliki AR, Sabih A, Al-abbasi FA, Ahmad A, Afzal M, Kazmi I, Khan R. Cancer initiating properties of erythrosine supplemented with sub necrotic dose of diethyl nitrosamine: potential effects on biochemical parameters of liver, Vitamin C and E. Mol Cell Toxicol 2015;11:357-66. [DOI: 10.1007/s13273-015-0036-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Brochard C, Hamy A, Michalak S, Aubé C, Picquet J, Nebout N, Caroli-Bosc FX, Oberti F, Calès P, Boursier J. Metastatic hepatocellular carcinoma: when surgery and successive palliative treatments lead to remission. Clin Res Hepatol Gastroenterol 2014;38:e19-22. [PMID: 23608740 DOI: 10.1016/j.clinre.2013.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Gerardi AM, Stoppino LP, Liso A, Macarini L, Landriscina M. Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. Oncol Lett 2013;5:975-7. [PMID: 23426789 DOI: 10.3892/ol.2013.1131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
8 Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma. Case Rep Gastroenterol. 2015;9:285-290. [PMID: 26351418 DOI: 10.1159/000438746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
10 Calistri L, Cordopatri C, Nardi C, Gianni E, Marra F, Colagrande S. Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Mol Clin Oncol 2017;6:389-96. [PMID: 28451419 DOI: 10.3892/mco.2017.1132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
11 Poullenot F, Bioulac-Sage P, Laumonier H, Saric J, Carteret T, Blanc JF. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases. Acta Oncol 2014;53:420-3. [PMID: 23713857 DOI: 10.3109/0284186X.2013.795286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol 2013; 5(2): 38-42 [PMID: 23556056 DOI: 10.4251/wjgo.v5.i2.38] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
13 Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol 2013;1:241-8. [PMID: 24649154 DOI: 10.3892/mco.2012.48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Liu D, Liu A, Peng J, Hu Y, Feng X. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res 2015;20:12. [PMID: 25649133 DOI: 10.1186/s40001-015-0085-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
15 Ahn SY, Lee HS, Kweon YO, Tak WY, Park SY. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. Dig Dis Sci. 2013;58:1428-1432. [PMID: 23306847 DOI: 10.1007/s10620-012-2522-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, Sakamoto H. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol 2016; 22(42): 9445-9450 [PMID: 27895433 DOI: 10.3748/wjg.v22.i42.9445] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kee KM, Hung CH, Wang JH, Lu SN. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. Onco Targets Ther. 2014;7:829-834. [PMID: 24920924 DOI: 10.2147/ott.s61740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
19 Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, Cabrera R, Nelson DR, Liu C. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Invest 2013;93:8-19. [PMID: 23108376 DOI: 10.1038/labinvest.2012.144] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
20 Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kanayama M, Matsui T, Kikuchi Y, Ishii K, Igarashi Y. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 2014;7:50-52. [PMID: 24348819 DOI: 10.3892/ol.2013.1664] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21:287-294. [PMID: 26527250 DOI: 10.3350/cmh.2015.21.3.287] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
22 Kim TS, Kim JH, Kim BH, Lee YS, Yoo YJ, Kang SH, Suh SJ, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clin Mol Hepatol 2017;23:340-6. [PMID: 28633200 DOI: 10.3350/cmh.2016.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kim SB. Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment. Case Rep Gastroenterol 2021;15:610-5. [PMID: 34616264 DOI: 10.1159/000514529] [Reference Citation Analysis]
24 Mizukami H, Kagawa T, Arase Y, Nakahara F, Tsuruya K, Anzai K, Hirose S, Shiraishi K, Shomura M, Koizumi J, Tobita K, Mine T. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012;5:380-384. [PMID: 23525021 DOI: 10.1159/000341259] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
25 Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587 [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]